Top broker says this ASX tech share has over 30% upside

This tech share could have huge upside potential…

| More on:
A young female investor sits in her home office looking at her ipad and smiling as she sees the QBE share price rising

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It has been a disappointing year for the CogState Limited (ASX: CGS) share price.

Since the start of 2022, the neuroscience technology company's shares have tumbled 43% to $1.45.

Is the CogState share price in the buy zone?

One leading broker that believes the CogState share price is great value after this decline is Bell Potter.

According to a note, the broker has retained its buy rating with a slightly trimmed price target of $1.95.

Based on the current CogState share price, this implies potential upside of 34% for investors over the next 12 months.

What did the broker say?

Bell Potter highlights that CogState appears well-placed to benefit from a significant increase in therapies aiming to treat Alzheimer's disease. This increased activity bodes well for demand for the company's brain health assessments. It explained:

With currently no disease modifying therapies (DMT) available, there has been an increasing interest in identifying potential treatments. The number of unique agents under investigation has increased from 93 in 2016 to 143 in 2022. The amyloid hypothesis has been a critical target for these therapies with important Phase 3 trials underway and results on the horizon.

In addition, the broker highlights that CogState has a material revenue backlog and notes that demand is increasing for other indications.

Cogstate currently has US$139.1m in contracted revenue backlog: US$100.2m in clinical trials and US$38.9m in healthcare (EISAI agreement). 84% of new clinical trial contracts in FY22 were in AD which reflects the strong relationship with CGS. Whilst there has been increasing utilisation of CGS technology in other indications such as Parkinson's Disease, Rare Paediatric Disorders and Depression, these studies are usually of lower contract sizes (safety endpoints, smaller cohort sizes).

All in all, the broker believes this will underpin solid sales and earnings growth through to at least FY 2025. In fact, by then, the broker expects CogState's revenue to be $79.8 million and its EBIT to be $18.4 million. This will be a 77.3% and 72% increase, respectively, over FY 2022's numbers.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CogState Limited. The Motley Fool Australia has positions in and has recommended CogState Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Technology Shares

A young woman lifts her red glasses with one hand as she takes a closer look at news about interest rates rising and one expert's surprising recommendation as to which ASX shares to buy
Technology Shares

WiseTech share price higher on big news

This tech stock has found its new leader.

Read more »

Man holding a calculator with Australian dollar notes, symbolising dividends.
Technology Shares

$10,000 invested in DroneShield shares 5 years ago is now worth…

You might be laughing all the way to the bank if you had done this.

Read more »

Happy woman working on a laptop.
Technology Shares

Up 60% since April, why this $40 billion ASX 200 tech stock remains a 'compelling buy' today

A leading expert believes this $40 billion ASX 200 tech stock has a lengthy growth runway ahead of it yet.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Technology Shares

DroneShield shares sink 7% despite big news

Let's see what's going on with this market darling on Thursday.

Read more »

A man activates an arrow shooting up into a cloud sign on his iPad.
Technology Shares

Up 25% since April, is it too late to buy Xero shares today?

A leading expert gives his verdict on the growth outlook for Xero shares.

Read more »

Man looking at digital holograms of graphs, charts, and data.
Technology Shares

2 amazing ASX tech shares I wish I'd bought last year

These tech companies are among the world’s best companies.

Read more »

A man in a business suit and tie places three wooden blocks with the numbers 1, 2, and 3 on them on top of each other.
Broker Notes

3 reasons to buy this booming ASX All Ords tech stock today

A leading broker forecasts more gains to come from this surging ASX All Ords tech stock.

Read more »

Man ponders a receipt as he looks at his laptop.
Technology Shares

Brokers rerate 3 leading ASX 200 tech stocks

Experts reveal their ratings on the ASX 200 tech sector's three biggest companies.

Read more »